OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
OrthoPediatrics (Nasdaq: KIDS) announced an exclusive U.S. distribution agreement with OSSIO to supply OSSIOfiber bio-integrative, metal-free fixation implants to children’s hospitals nationwide.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OrthoPediatrics (Nasdaq: KIDS) announced an exclusive U.S. distribution agreement with OSSIO to supply OSSIOfiber bio-integrative, metal-free fixation implants to children’s hospitals nationwide.
The technology is designed for pediatric fractures and deformities, gradually integrating into bone within 18–24 months and aiming to reduce secondary hardware removal surgeries.
Positive
- Exclusive U.S. distribution rights for OSSIOfiber pediatric fixation implants
- Expansion of product portfolio in pediatric trauma and deformity care
- Technology designed to reduce secondary hardware removal surgeries
- Bio-integrative implants that fully integrate into bone within 18–24 months
Negative
- None.
Details
News Market Reaction – KIDS
On Jun 24, the day this news came out, KIDS closed 4.16% above the previous close. That session’s volume was 1.7x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jun 24 session.
Key Figures
- Bone integration timeline
- 18–24 months
- Time for OSSIOfiber implants to fully integrate into bone tissue
- Q1 2026 revenue
- $59.4M
- Reported in Q1 2026 financial results
- Revenue growth
- 13%
- Year-over-year increase in Q1 2026 revenue
- 2026 revenue guidance
- $263.0M–$267.0M
- Full-year 2026 guidance raised on Apr 30, 2026
- Adjusted EBITDA
- $2.2M
- Q1 2026 adjusted EBITDA reported
- Free cash flow usage
- $5.0M
- Q1 2026 free cash flow usage after 40% improvement
- Short interest
- 5.34%
- Reported short interest as of May 29, 2026
- Days to cover
- 7.61 days
- Calculated on reported short interest and volume
Historical Context
-
Participation in Goldman Sachs Global Healthcare Conference fireside chat.
-
Q1 2026 results with revenue growth and raised full‑year guidance.
-
Launch of TRAXIO Complete Halo Gravity Traction system for pediatric spine.
-
Announcement of date and webcast details for Q1 2026 results.
-
Planned fireside chat at Needham Virtual Healthcare Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
bio-integrative medical
fixation technology medical
post-implantation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARSAW, Ind., June 24, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced an exclusive distribution agreement with OSSIO, Inc. (“OSSIO”) that brings U.S. children’s hospitals nationwide a bio-integrative, metal-free fixation technology ideally suited for treatment of fractures and deformities in pediatric patients.
After performing their fixation function, OSSIOfiber® implants are gradually replaced by the patient’s newly formed bone during the natural healing process. This technological advance in material science decreases the need for hardware removal surgeries that pediatric patients who initially receive metal implants usually receive.
“Existing fixation technology requires pediatric orthopedic surgeons to consistently remove their patients’ metal implants in a second surgery that adds cost and risk,” said Joe Hauser, President of Trauma and Deformity at OrthoPediatrics. “OSSIOfiber implants reduce the rate of these secondary procedures by doing away with metal. From a strategic perspective, partnering with OSSIO expands our reach and capabilities with a revolutionary technology that complements OrthoPediatrics’ current product offering, allowing us to address more unmet pediatric needs while strengthening the company’s long-term growth potential.”
OSSIOfiber implants are made from a proprietary blend of natural mineral fibers that provide initial fixation strength comparable to traditional metal implants while safely and completely integrating into the patient’s own bone tissue within 18–24 months post-implantation, leaving no hardware behind.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets nearly 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.